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ABSTRACT  
 Candida is an opportunistic pathogen that causes mucosal and deep systemic 
candidiasis. The emergence of drug resistance, and the side effects of currently 
available antifungals have restricted their use as long-term prophylactic agents for 
candidal infections. Given this scenario, probiotics have been suggested as a useful 
alternative for the management of candidiasis. We analyzed the available data on the 
efficacy of probiotics in candidal colonization of host surfaces. A number of well-
controlled studies indicate that probiotics, particularly lactobacilli, suppress Candida 
growth and biofilm development in vitro. A few clinical trials have also shown the 
beneficial effects of probiotics in reducing oral, vaginal and enteric colonization by 
Candida, alleviation of clinical signs and symptoms and in some cases, reducing the 
incidence of invasive fungal infection in critically ill patients. Probiotics may serve in 
future as a worthy ally in the battle against chronic mucosal candidal infections. 
  
 3 
INTRODUCTION 
The high prevalence of the human immunodeficiency virus (HIV) infection 
and other immune compromised populations globally has resulted in resurgence of 
Candida infections. These infections may be present on mucosal surfaces, including 
the oral cavity, oropharynx, esophagus, and vagina, as well as systemically [1]. 
Healthy individual may also be the target of Candida infections as this fungus 
is a commensal organism in human mucosal surfaces, inhabiting one half of the 
human populace as an opportunist pathogen of the gastrointestinal and urogenital 
tracts [2]. When adverse conditions supervene particularly in debilitated individuals, 
Candida is capable of causing superficial as well as deep invasive candidiasis, 
including fungaemias. These diseases are essentially caused by candidal biofilms 
attached to body surfaces as opposed to the planktonic form of the yeast which exist is 
the suspended phase. Candida albicans is the most common Candida species 
inhabiting the mucosal surfaces both in health and disease, while other species such as 
C. tropicalis, C. guilliermondii, C. krusei, C. tropicalis, and C. glabrata are less 
frequently isolated.  
A range of adverse factors predisposes an individual to local or systemic 
candidal infection. The critical factors that precipitate systemic infections include the 
very low birth weight neonates [3] and immunosuppression as in HIV disease, or 
radiation and cytotoxic therapy [4]. Perturbation of mucosal ecosystem or marked 
changes in the microbial ecosystems due to antibiotics or corticosteroids; 
hypoendocrine states such as hypothyroidism, Addison’s disease and diabetes 
mellitus; blood disorders such as acute leukaemia; xerostomia due to irradiation or 
Sjogren’s syndrome, and ill-fitting appliances are predisposing factors for localized 
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candidal infections either in health or diseased states [4]. Thus, Candida is considered 
as an opportunistic pathogen, causing ‘diseases of the diseased’.  
The aim of this review was to explore critically the available in vitro and in 
vivo data on the efficacy of probiotic therapy in managing mucosal candidiasis. For 
this purpose a critical review of the literature was conducted to select pertinent 
articles published in the English literature from 2000 to 2015. An electronic search 
was performed in MEDLINE using the following terms: ‘probiotic or Lactobacillus’ 
AND ‘Candida or candidiasis’ to garner clinical evidence, and ‘probiotic or 
Lactobacillus’ AND ‘Candida’ for the in-vitro studies. Only clinical trials assessing 
Candida infection in the oral cavity, urogenital and gastrointestinal tract were 
included.  
In the following sections we provide an overview of Candida infections, a 
summary of probiotics, in vitro and in vivo evidence of the antifungal effects of 
probiotics, and their possible mechanisms of action, and finally, the safety and risks 
of probiotic therapy. 
 
CANDIDA INFECTIONS 
Oral Candidiasis 
Oral candidiasis can manifest in a variety of clinical guises. The classic triad 
of oral candidiasis is the pseudomembranous, the erythematous (atrophic) and 
hyperplastic variant [4]. 
In addition, there are a number of other Candida-associated lesions where the 
aetiology is multifactorial. These diseases include Candida-associated denture 
stomatitis, angular cheilitis or angular stomatitis, median rhomboid glossitis and the 
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newly described linear gingival erythema, the microbial aetiology of which is still ill 
understood [4].  
 
Extra-oral and systemic Candida infections 
 Vulvovaginal candida infection (VVC) is the second most common cause of 
vaginitis after bacterial vaginosis. Transmission of this yeast from the vagina to the 
mouths of newborns during birth is a major portal of oral infections in newborns, 
leading to the development of thrush [2]. 
 Candida inhabits the gastrointestinal tract (GIT) in almost all humans and most 
of the infections involving Candida are endogenously acquired from the GIT. 
Candida can translocate into the blood stream through the intact gastrointestinal 
mucosa and spread to visceral organs, leading to systemic candidiasis, especially in 
critically ill patients [3]. Disruption of normal physiological barriers, such as gastric 
acidity and perturbations of the indigenous microflora of the colon, facilitate Candida 
overgrowth. 
 Within the GIT, the most common site of infection is the esophagus. Candida 
may be associated with gastric ulcers, as an opportunistic pathogen that delays ulcer 
healing and aggravates the disease [5]. 
 
Management of candidiasis  
 For some decades, systemic antifungal agents have been successfully used to 
prevent mucosal as well as invasive fungal infections. However, due to the drug side 
effects (nausea, vomiting and diarrhea), and potential emergence of resistant strains, 
antifungal prophylaxis has not been totally successful.  
 The commonly used antifungals are the polyenes (Nystatin and amphotericin B) 
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and azoles (fluconazole, itraconazole, voriconazole). Interestingly, the biofilm phase 
of Candida is much more resistant to all these antifungals compared with their 
planktonic counterparts [6]. The limited spectrum and toxicity of available antifungals, 
and the gradual emergence of resistance to these drugs are a concern, thus alternative 
therapies are urgently warranted. 
 
PROBIOTICS 
The use of probiotic bacteria against microbial infections has emerged as an 
alternative therapeutic technique for Candida infections in view of the limitations of 
the currently available antimicrobials.  
Probiotics are defined as live microorganisms that when administered or 
consumed in adequate quantities confer health benefits on the host. Bacteria 
belonging to the genera Lactobacillus and Bifidobacterium and, to a lesser extent, 
Enterococci, Streptococcus and Saccharomyces have often been used as probiotics in 
food supplements for a considerable period of time [7].  
A safe probiotic needs to be of human origin, devoid of intrinsic and 
transmissible antibiotic resistance genes. The functional requirements of a probiotics 
include acid and bile tolerances, adequate adherence and colonization on epithelial 
surfaces, immunestimulation, and antagonistic activity against pathogens [7].  
 
Therapeutic potential of probiotics  
In therapeutic terms probiotics are known to reduce Candida infections in 
different organ systems of the human body, and generally considered to be beneficial 
for overall health. For instance probiotics can combat diarrhea, mainly in children, 
relieve lactose intolerance and symptoms of inflammatory bowel diseases [7]. 
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Additionally, probiotic bacteria have been investigated for their potential for 
preventing cancers such as colorectal cancer [8], regulating blood pressure [9] and 
suppressing cholesterol levels [10]. The combination of probiotics with traditional 
treatment options are thought to generate better outcomes and disease resolution in 
different loci with only a marginal increase in the treatment cost [7, 11, 12]. 
 
Probiotics as an antimicrobial 
Organisms of the genus Lactobacillus have been traditionally used as 
probiotics for decades and they are deemed worthy as an alternative biological 
approach to combat bacterial and fungal pathogens in the oral cavity, GIT and 
urogenital system [1, 3, 11, 13-21]. It is noteworthy that the antimicrobial effect of 
probiotic bacteria is strain-specific, and hence the selection of probiotics for 
therapeutic purposes should be targeted for specific pathogens and their beneficial 
effects cannot be generalized [14]. Additionally there are reports of putative anti-viral 
effect of probiotics mainly against respiratory viral pathogens in people of all ages 
[22].  
 
IN VITRO EVIDENCE OF THE ANTIFUNGAL EFFECTS OF PROBIOTICS 
A number of in vitro studies have demonstrated the antifungal effect of 
polymicrobial combinations of probiotics against human C. albicans isolates from the 
oral cavity, GIT, and genitourinary tract [13, 14, 23-31]. Table 1 illustrates the variety 
and the extent of bacterial strains used to evaluate the candidicidal activity of 
probiotic bacteria, beginning this millennium.  
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The probiotic bacteria that have been investigated against Candida species to 
date, include Streptococcus salivarius K12 [23], Lactobacillus rhamnosus GR-1, L. 
reuteri RC-14 [25], and also clinical isolates of Lactobacillus [27, 30].  
Antimicrobial activity of lactobacilli is generally well known. Studies using 
antagonism in agar diffusion assays have demonstrated that Lactobacillus species 
inhibit the growth of both Gram-positive and Gram-negative pathogens (e.g. S. 
mutans and Escherichia coli, respectively) [13, 14], in addition to Candida spp. [13, 
14, 25, 27, 30, 32]. C. albicans was found to be more susceptible to the antifungal 
effect of Lactobacillus than C. tropicalis [27]. Moreover, probiotic bacteria and their 
supernatant also exhibited growth inhibitory activities against C. glabrata [32]. The 
production of hydrogen peroxide by the probiotics that antagonizes candidal growth 
was a notable phenomenon observed in a number of these studies [27, 30].  
Hyphae formation and adhesion assays were used to evaluate the effect of 
Saccharomyces boulardii [26] and Streptococcus salivarius [23] on C. albicans. S. 
boulardii appears to secrete an active compound that inhibits filamentation of C. 
albicans and its mycelial development, a crucial virulence attribute of this fungal 
pathogen. S. salivarius K12 was not directly fungicidal, but appeared to inhibit 
Candida adhesion to the substratum and increase the planktonic cells in culture 
medium [23].  
The effect of probiotics may be time dependent. Using a time-kill assay, some 
investigators have attempted to reinforce the probiotic effect of bacteria by 
supplementing the medium with chemical adjuvants, such as selenium. The latter is 
an essential micro-mineral that regulates metabolism, and is known to reinforce 
immunity. Selenium nanoparticle-enriched L. plantarum and L. johnsonii cells and 
supernatant have shown higher antifungal activity against C. albicans than controls 
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devoid of the nanoparticles [24]. These data, yet to be confirmed, exemplify how 
probiotics could be synergized and deserve further studies. 
Experiments on the effect of probiotics on Candida biofilms, as opposed to 
their suspended planktonic phase, provide another fascinating glimpse of how 
probiotics behave [28, 29, 31]. It has been shown that a number of bacteria can 
interfere with the biofilm growth by reducing hyphal development [28, 31], a result 
akin to that described above [26]. Ujaoney et al. [29] reported that the probiotic cell-
free supernatant had a strong and significant inhibitory effect on biofilm development 
on denture acrylic strips than the bacteria per se, indicating that the inhibitory agent is 
an exometabolites secreted into the medium.  
Chew et al. [32], using confocal laser scanning microscopy, also demonstrated 
the candidicidal effect of planktonic lactobacilli and their supernatant against C. 
glabrata, another common fungal pathogen.  
A summarized in Table 1, there is now a convincing body of in vitro data to 
indicate the antifungal effect of probiotics against Candida spp. The challenge now is 
to clarify the mechanisms involved and harness these in further translational work. 
Investigations of the molecular mechanisms underlying the probiotic effect using 
gene expression and related technology are likely to yield interesting data in this 
regard.  
 
IN VIVO EVIDENCE OF THE ANTIFUNGAL EFFECTS OF PROBIOTICS  
 As opposed to the in vitro studies reported above, a number of in vivo studies 
have also been performed over the past decade or so to substantiate the antifungal 
activity of probiotics humans (Table 2). The oral cavity, gastrointestinal and 
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urogenital tract have been the major loci of investigation as these sites are susceptible 
to Candida infections. 
 
Oral cavity 
 Despite the high prevalence of oral candidal infections in predisposed 
populations the world over, and the recalcitrance and chronicity of these diseases, 
there are only a few in vivo studies evaluating the effect of probiotics on suppressing 
oral candidiasis. These indicate that probiotics may be a useful adjunct in the battle 
against oral candidiasis especially as a prophylactic agent in immunocompetent 
individuals. 
The elderly are a particular group susceptible to oral candidiasis even in health, 
due to the prosthesis (dentures) they frequently wear and hyposalivation. Their 
weakened immune status may favor the recurrence of candidiasis. Two research 
groups have shown that the daily consumption of lactobacilli - laced cheese [15] or 
lozenges [17] significantly reduce the high yeast counts in saliva and biofilms in the 
elderly. Since biofilms on oral prosthetic devices act as potent reservoirs of the yeast, 
the mechanical removal of biofilms associated with the regular use of probiotics that 
reduce the oral burden of Candida could play a major role in preventing oral 
candidiasis in denture wearers. Interestingly, one study reported increased salivary 
flow as a salutary accompaniment to probiotic administration [15]. 
As mentioned full denture wearers suffer frequently from Candida-associated 
denture stomatitis [4], which lowers the quality of life. Ishikawa et al. [16] have 
reported that a probiotic product, when regularly placed on the palatal surface of 
maxillary dentures, reduced oral candidal burden in healthy denture wearers. These 
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preliminary data imply that multispecies probiotics, together with good denture 
hygiene may help suppress recurrence of these chronic infections [11]. 
Commercial food products with probiotics are common worldwide. A widely 
available probiotic-laced drink containing Lactobacillus casei and Bifidobacterium 
breve was able to reduce the prevalence of oral Candida in healthy individuals [33]. A 
significant increase in anti-Candida IgA levels was associated with probiotic 
consumption [33]. In contrast, the identical product did not significantly affect the 
oral candidal colonization in complete denture wearers [34] and in healthy dentate 
people [35], after four weeks of administration. The lower dose of probiotic intake 
and the small number of individuals included in the latter studies may explain these 
divergent observations.  
 
Urogenital tract 
 Chronic vulvovaginal candidiasis (VVC) is a widely prevalent disease and 
impacts the life quality of thousands of women the world over. Although standard 
antifungals are effective, there is no alternative approach for suppressing these 
recalcitrant infections. Several groups have therefore evaluated the efficacy of 
probiotics in the treatment and prophylaxis of VVC [1, 2, 12, 36].  
 Two studies conducted on healthy women have reported that the co-
administration of probiotics with standard antifungal therapy (fluconazole) was more 
effective in reducing symptoms of VVC, including vaginal discharge, pruritus vulvae, 
vulva and vagina erythema, dyspareunia and dysuria, than in a group treated with 
antifungals alone [12, 36]. Clinical improvement was also observed after local 
administration of a commercial slow release probiotic product alone, without an 
antifungal agent, in healthy women with recurrent VVC [2]. Similarly, in a study 
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conducted in immunocompromised women, who are highly susceptible to recurrent 
and complicated VVC infection, probiotic yoghurt consumption led to a decreased 
frequency of infection [1]. 
On the contrary, another well controlled study reported that probiotic bacteria 
taken both orally and locally was unable to prevent post-antibiotic VVC in 
immunocompetent individuals who took oral antibiotics [37]. Qualitative and 
quantitative differences in the probiotics strains, as well as the period of probiotics 
administration are likely to be the reasons for the divergent results between the 
foregoing studies. 
 
Gastrointestinal tract 
 Candida species are common inhabitants of the gastrointestinal tract (GIT) of 
humans. Perturbation of the local microbiome however leads to dysbiosis within this 
ecosystem, leading to candidal overgrowth and possible invasive infections, 
especially in infants [21]. 
 Hence, immunocompromised children, especially preterm neonates with low 
birth weight, have been the target population of number studies evaluating the 
efficacy of probiotics against candidal colonization of GIT [3, 19-21]. Within this 
population, most researchers have reported a significant reduction in the incidence 
and intensity of enteric candidal colonization with probiotic-laced human milk, 
administered either with or without concurrent antifungals [19-21]. Important 
secondary effects of the probiotics observed in these studies include reduction of 
sepsis episodes [3], early establishment of full feeding associated with reduction in 
the duration of hospitalization [20], and the decrease in the incidence of abnormal 
neurological outcomes associated with late-onset sepsis [21].  
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Broad-spectrum antibiotics are notorious for their ability to cause GIT 
dysbiosis and candidiasis [18, 37]. In immunocompetent children who had received 
broad-spectrum antibiotics, probiotic therapy led to a reduction of gastrointestinal 
candidal colonization as well as candiduria – a surrogate marker of invasive fungal 
infection [18]. 
 
POSSIBLE MECHANISMS OF ACTION OF PROBIOTICS  
Clearly the major attribute of probiotics appears to be the restoration of a 
natural healthy microbiome in a given habitat, turning from a catastrophic, disease-
inducing, dysbiotic microbiota to a healthy, symbiotic, stable equilibrium. A number 
of hypothesis, most unproven as yet, have been proposed for the genesis of this well-
balanced state from disease to health. Probiotics may compete for nutrients and 
receptors on the cell surfaces with the pathogenic microorganisms, thus preventing 
their adhesion and colonization on the mucosal surfaces [2, 29]. Co- and auto-
aggregation of probiotics with the formation of a critical mass required for a healthy 
biofilm development may act as a protective lining against pathogenic infection [30]. 
Apart from the above, the production of biosurfactants that interfere with microbial 
adhesion and desorption [38], the release of exometabolites, such as lactic, acetic and 
capric acid, ,and the production of bacteriocins and hydrogen peroxide (H2O2) are 
other possible attributes postulated as mechanisms for probiotic activity [24-26]. 
Despite such in vitro data on the inhibitory effect of probiotic products on yeasts, the 
direct effect of probiotics on mucosal candidiasis is yet be shown in a laboratory 
environment mimicking the oral cavity, vagina or the GIT. 
 The host response to probiotics is likely to play an important role in probiotic 
mediated microbiome effects. The modulation of both innate and adaptive immune 
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systems is probably associated with alteration of cytokines profile and Candida 
recognition by epithelial and immune defense cells [28, 39, 40]. Evidence to imply 
probiotic interference with these host defense factors during candidal infestation is 
still needed. 
With respect to candidal infection, probiotics were found to reduce 
filamentation and biofilm development in C. albicans, two key virulence attributes of 
this fungus [25, 28]. As the yeast form of Candida, as opposed to the hyphal form, is 
more susceptible to phagocytosis [40], probiotics appear to assist the host combat the 
pathogen more effectively by suppressing filamentation. Despite the evidence that 
probiotic bacteria may affect the expression of genes associated with biofilm 
formation and filamentation of Candida species [25], the mechanisms by which 
probiotics affect these yeasts attributes are still unclear.  
Probiotics administered in tandem with antifungal drugs synergizes clearance 
of Candida [11, 12, 36]. Apart from the obvious antifungal effect of the drug, the role 
of the probiotic under these conditions remains to be elucidated. The increased 
expression of stress-related genes and decreased expression of genes involved in drug 
resistance in Candida, promoted by the probiotics, would possibly increase the fungus 
susceptibility to the antifungal agent administered [25].  
 
SAFETY AND RISKS OF PROBIOTIC THERAPY 
A range of bacteria has been utilized as probiotics in humans, depending on 
the pathological condition. None of the clinical studies mentioned above have 
reported adverse effects directly related to probiotics, suggesting their safety. 
Nevertheless, the safety, efficacy and functionality of probiotics bacteria should be 
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tested in healthy as well as in compromised individuals prior to their administration as 
therapeutic agents. 
 
FUTURE PERSPECTIVES AND CONCLUSIONS 
In summary, clinical studies indicate that probiotics may reduce Candida 
colonization on human mucosal surfaces, relieve signs and symptoms of fungal 
infection, and enhance the antifungal effect of conventional therapy, implying that 
probiotics have the potential to sustain a healthy mucosal microbiota, acting both as 
prophylactic and adjunctive therapy against candidiasis. In vitro studies indicate that 
the antifungal effect of probiotics is likely to be due to their interference with 
Candida biofilm development and hyphal differentiation. However, it is premature to 
designate probiotics as an alternative to antifungals, as yet, due to the paucity of 
available clinical trials. In particular, case control clinical trials with adequate patient 
numbers are warranted not only to ascertain the activity of the probiotic formulations, 
but also to evaluate their dosage, administration schedules, side effects, and bio-
dynamics in humans. As with any formulations of live organisms, other concerns that 
need further investigation include the potential for selection of resistant strains, 
mutability, and tolerability on prolonged use, as well as pathogenic potential in 
immunocompromised patients. Given these caveats probiotics may serve in future as 
worthy allies in the battle against chronic mucosal fungal infections. 
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Table 1. In vitro investigations on the antifungal effects of probiotics. 
REFERENCE PROBIOTICS PATHOGEN METHOD RESULTS COMMENTS 
Strus et al. 2005 
[27] 
14 different strains:  
L. fermentum, L. 
rhamnosus, L. plantarum, 
L. acidophilus 
- C. albicans  
- C. pseudotropicalis 
- Antagonism on agar 
plates 
- All probiotics inhibited the growth of C. albicans 
to a certain degree;  
- Most Lactobacillus were able at least slightly 
inhibit the growth of C. pseudotropicalis. 
Anticandidal activity related to 
H2O2 production and alternative 
mechanism. 
Thein et al. 2006 
[28] 
L. acidophilus, 
Actinomyces israelii, 
Prevotella nigrescens, 
Porphyromonas gingivalis, 
Pseudomon aeruginosa, 
Escherichia coli, 
Streptococcus mutans, and 
S. intermedius 
C. albicans 2560g - Biofilm assay 
(scanning electron 
microscopy) 
- 48 h co-culture: all bacteria, exept S. mutans and 
S. intermedius, reduced viable yeasts cells;  
- C. albicans biofilm + P. aeruginosa: reduced 
hyphal growth compared with bacteria-free 
biofilm. 
Bacteria modulate C. albicans 
biofilm formation in mixed species 
co-cultures and affected the 
morphogenesis of the yeast. 
Hasslöf et al. 
2010 [13] 
L. plantarum 299v, L. 
plantarum 931, L. 
rhamnosus GG ATCC 
53103, L. rhamnosus 
LB21, and L. paracasei 
Mutans streptococci 
(MS): 
- Reference strains: S. 
mutans NCTC 10449, S. 
mutans Ingbritt, and S. 
sobrinus OMZ176 
- Clinical isolates: S. 
mutans P1:27 and S. 
mutans P2:29 
- Agar overlay 
interference tests. 
Four concentrations 
of probiotics were 
tested (109, 107, 105, 
and 103 CFU/ml) 
MS: 
- 109 to 105 CFU/ml: all lactobacilli strains 
inhibited the growth of the MS strains completely 
(except L. acidophilus La5); 
- 103 CFU/ml: only L. plantarum 299v and L. 
plantarum 931 displayed a total growth inhibition 
for all MS. L. rhamnosus GG ATCC 53103 
inhibited the growth slightly for three MS. 
L. acidophilus La5: weaker 
inhibition capacity in comparison 
with the other probiotic strains 
(p<0.05).  
All the tested Lactobacillus strains 
reduced Candida growth, but the 
effect was generally weaker than 
for MS. 
Table
Candida albicans: 
- Reference strains: C. 
albicans ATCC 28366, 
C. albicans ATCC 10231 
- Clinical isolates: C. 
albicans 1957, C. 
albicans 3339 and C. 
albicans GDM8 
Candida albicans: 
- 109 and 107 CFU/ml: all lactobacilli except L. 
acidophilus La5 and L. reuteri PTA 5289 
inhibited all Candida strains completely; 
- 105 CFU/ml: L. rhamnosus strains, L. paracasei 
and L. reuteri PTA 5289 displayed a slight 
inhibition. L. acidophilus La5 showed no 
inhibition. L. plantarum and L. reuteri ATCC 
55730 executed a total inhibition; 
- 103 CFU/ml: no inhibition was recorded except 
for the L. plantarum strains. 
Murzyn et al. 
2010 [26] 
Saccharomyces boulardii C. albicans SC5314 - Hyphae formation assay 
- Adhesion assay 
- Gene expression assay 
 
- Active compounds of probiotic yeast reduced 
Candida virulence factors (hyphae formation, 
cells adhesion, and biofilm formation);  
- Yeast extract and capric acid reduced expression 
of HWP1, INO1 and CSH1 genes in C. albicans 
cells. 
Capric acid was the main 
compound affecting hyphae 
formation, Candida adhesion and 
biofilm formation. 
Ishijima et al. 
2012 [23] 
Streptococcus salivarius 
K12 
C. albicans (clinical 
isolate) 
- Germ tube formation 
and mycelial growth 
of C. albicans 
(adherence to plastic 
substratum) 
- Deferred streak assay 
- S. salivarius reduced adherence of mycelial form 
to plastic substratum, increased the number of 
planktonic Candida cells in culture medium, but 
did not inhibit C. albicans strain; 
- Probiotic bacteria preferentially bound to hyphae. 
S. salivarius K12 was not directly 
fungicidal, but appeared to inhibit 
Candida adhesion to the 
substratum.  
Köhler et al. L. rhamnosus GR-1 and L. C. albicans SC5314. - Antagonism on agar - 48 h: Lactobacillus GR-1 and RC-1 showed Lactic acid at low pH environment: 
2012 [25] reuteri RC-14  
L. johnsonii PV016 and 
Staphylococcus aureus 
ATCC 25923 (controls) 
plates and in broth 
cultures 
visible zones of fungal growth inhibition around 
them; 
- L. johnsonii: very weak inhibition zone;  
- S. aureus: no inhibition zones; 
- C. albicans growth was suppressed at low pH by 
the Lactobacillus culture supernatants; 
- Probiotics inhibited genes associated with biofilm 
formation. 
major role in fungal growth 
inhibition. Glucose or other 
nutrient exhaustion was not a likely 
cause for fungal inhibition. H2O2 
production may be an anti-Candida 
factor. 
Coman et al. 
2014 [12] 
L. rhamnosus IMC 501® - Gram-positive, Gram-
negative bacteria 
- C. albicans, C. 
glabrata, C. krusei, C. 
parapsilosis, and C. 
tropicalis 
- Modified cross-streak 
method 
- Radial streak method 
- Agar well diffusion 
method  
L. rhamnosus 
- Inhibitory activity against both Gram-positive and 
Gram-negative bacteria, and against two C. 
albicans strains (ATCC 10261 and ISS7). 
L. paracasei IMC 502®: higher 
activity towards all the pathogens, 
especially Candida strains; 
Strong inhibition registered for 
SYNBIO®. 
L. paracasei IMC 502® 
L. paracasei 
- Inhibitory effect on Gram-positive and Gram-
negative bacteria, especially S. aureus and 
Proteus mirabilis. All Candida spp. were 
inhibited except C. glabrata and C. tropicalis. 
Combination of both 
(SYNBIO®) 
SYNBIO® 
- Inhibitory activity against most of the bacteria and 
fungi strains, especially C. albicans and C. 
krusei. 
Verdenelli et al. 
2014 [30] 
L. paracasei subsp. 
paracasei, L. plantarum, L. 
fermentum, L. rhamnosus 
IMC 501®, and L. 
- C. albicans, C. 
glabrata, C. krusei, C. 
parapsilosis, C. tropicalis 
- Agar well diffusion 
assay and radial 
method  
- Well diffusion assay: no inhibition against 
Candida spp; 
- Radial method: all lactobacilli had the capacity to 
Inhibition and coaggregation 
ability vary according to the 
Lactobacillus strain and the 
paracasei IMC 502® (clinical isolates) - Coaggregation assay inhibit Candida in different degrees. pathogen involved. 
Kheradmand et 
al. 2014 [24] 
L. plantarum (ATCC 8014) 
and L. johnsonii (clinical 
isolate) enriched or not 
with selenium dioxide 
nanoparticles (SeNPs) 
C. albicans (ATCC 
14053) 
- Conventional hole-
plate diffusion 
method and time-kill 
assay using probiotic 
supernatant (grown 
with or without 
selenium dioxide) 
Conventional hole-plate diffusion:  
- L. plantarum and L. johnsonii supernatant grown 
with selenium dioxide showed potent anti-
Candida activity.  
- No antifungal effect was observed with 
supernatant without selenium.  
Time-kill assay:  
- No viable C. albicans was present after 4 h 
incubation with culture supernatants grown with 
selenium dioxide.  
- Viable C. albicans cells were present even after 
24 h incubation with culture supernatants growth 
without selenium dioxide. 
Direct antifungal effect was 
observed when selenium-enriched 
Lactobacillus spp. were co-cultured 
with C. albicans. The strong 
inhibition of C. albicans by 
supernatant of selenium-enriched 
Lactobacillus species indicated the 
release of potent exometabolites. 
 
- Time-kill assay using 
probiotic cell 
suspension (grown 
with or without 
selenium dioxide) 
After 0.5 h, Lactobacillus strains without SeNPs 
decreased the viability of C. albicans by 
approximately 10-fold. SeNPs-enriched species 
decreased 1000-fold. 
Ujaoney et al. 
2014 [29] 
L. acidophillus, L. 
rhamnosus, L. salivarius, 
Bificunbacterium bifidum, 
Streptococcus 
thermophilus, B. infantis, 
C. albicans 10341 - Biofilm assay on 
denture strips using 
bacterial suspensions 
and probiotic 
supernatants (XTT 
Probiotics supernatant provided a stronger and 
significant inhibitory effect on biofilm formation 
than their bacterial counterparts. 
Depletion of nutrients in the culture 
media by overgrowth of the 
probiotic bacteria may inhibit 
fungal growth. 
   
Lactobacillus GG, and 
Bacillus coagulans BC30 
quantification) 
Vilela et al. 2015 
[31] 
L. acidophilus ATCC 4356 C. albicans ATCC 18804 - Biofilm assay and C. 
albicans filamentation 
assay using light 
microscope 
- L. acidophilus culture filtrate reduced the growth 
of C. albicans cells by 45.10%.  
- Less hyphae formation in the presence of L. 
acidophilus cells or culture filtrate. 
L. acidophilus produced substances 
with anti-Candida activity, 
presenting an indirect effect on 
Candida. 
Chew et al. 2015 
[32] 
Lactobacillus rhamnosus 
GR-1 and Lactobacillus 
reuteri RC-14 
Candida glabrata ATCC 
2001 and clinical isolates 
- Spot overlay assay; 
- Plate-based microtitre 
assay 
- Candida viability 
assay using confocal 
laser scanning 
microscopy; 
- Aggregation assay 
- Microbial adhesion to 
hydrocarbons 
(MATH) assay. 
- Probiotic strains exhibit growth inhibitory 
activities (bacterial cells and supernatant) and 
candidacidal activity against C. glabrata; 
- Both probiotic strains exhibited strong 
autoaggregation and coaggregation in the 
presence of Candida. 
Lactobacilli may prevent C. 
glabrata colonization through the 
formation of aggregates. Reduction 
of pH plays role on the antifungal 
effect of probiotic, but not H2O2. 
Other inhibitory mechanisms or 
pathways may be involved. 
Table 2. Clinical investigations on the antifungal effects of probiotics in the oral cavity, urogenital tract and gastrointestinal tract of humans. 
REFERENCE SITE OF 
ACTION 
PROBIOTIC  PATHOGEN METHOD RESULTS COMMENTS 
Hatakka et al. 
2007 [14] 
Oral cavity L. rhamnosus GG 
(ATCC 53103), L. 
rhamnosus LC705, 
Propionibacterium 
freudenreichii ssp 
shermanii JS 
- C. albicans, C. 
glabrata, C. krusei, 
and C. tropicalis 
- RCT, 276 elderly people; 
- Probiotic therapy: daily consumption of 
50 grams of probiotic cheese or control 
cheese for 16 weeks; 
- Community Periodontal Index (CPI) and 
mucosal lesions were recorded. 
Sampling for oral yeasts was undertaken. 
- Prevalence of yeast in saliva 
decreased in the probiotic group 
from 30% to 21% (32% reduction), 
and increased in the control group 
from 28% to 34%; 
- Probiotic intervention reduced the 
risk of high yeast counts by 75%. 
Probiotic reduced the 
prevalence of 
hyposalivation; 
No adverse events were 
observed.  
Mendonça et al. 
2012 [34] 
Oral cavity L. casei and 
Bifidobacterium 
breve 
- C. albicans, C. 
tropicalis, C. 
guilliermondii, C. 
glabrata, C. 
lipolytica, C. 
krusei, C. kefyr, and 
C. parapsilosis 
- 42 women (≥65 years); 
- Probiotic therapy: 3x per week for 30 
days; 
- Saliva sample collection for Candida 
cells quantification (CFU counting) and 
IgA analysis (ELISA). 
- Reduction of Candida prevalence 
from 92.9% to 85.7%; 
- Increase of anti-Candida IgA levels. 
C. albicans was the 
most frequently species 
isolated before and 
after probiotic 
consumption. 
Sutula et al. 2012 
[35] 
Oral cavity L. casei Shirota - Candida spp. 
- Streptococcus 
mutans and Gram-
negative anaerobic 
species 
- 7 healthy complete denture wearers (≥55 
years) 
- Probiotic therapy: 1x per day, with the 
denture in position, for 28 days; 
- Samples of saliva, tongue and denture 
biofilm were collected.  
- No effect of probiotic on occurrence 
and viability of Candida; 
- No significant change in the viability 
of Streptococcus mutans and Gram-
negative anaerobes. 
Small sample group (n 
= 7) completed the 
study protocol. 
Sutula et al. 2013 
[36] 
Oral cavity L. casei Shirota - Candida spp. 
- Gram-negative 
anaerobic species 
- 21 health dentate (18 – 45 years); 
- Probiotic therapy: 1x per day for 28 
days; 
- Saliva and tongue-coating samples were 
collected. Morning breath samples were 
obtained using portable sulphide 
monitors. 
- Lactobacillus level in saliva was 
increased during probiotic 
consumption period; 
- Candida and anaerobic species levels 
were unaffected by the therapy; 
- Morning breath scores measured 
were not significantly affected. 
Confirmation of the 
temporary and intake-
dependent presence of 
Lactobacillus. 
Li et al. 2014 
[17] 
Oral cavity L. bulgaricus, 
Bifidobacterium 
longum, and 
Streptococcus 
thermophilus 
Candida spp.  - RCT, 65 patients with Candida-
associated stomatitis;  
- Probiotic therapy: antifungal alone 
(sodium bicarbonate solution + nystatin 
paste) or associated with probiotic, 3x 
per day for 4 weeks; 
- Parameters of hyperaemia, visual 
analogue scale scores, culture of saliva 
and lingual dorsum swab were assessed. 
- Detection rate of Candida spp. was 
reduced in the probiotic group; 
- Significant relief of clinical signs 
and symptoms after probiotic 
administration. 
No adverse events were 
observed. 
Ishikawa et al. 
2015 [15] 
Oral cavity L. rhamnosus 
HS111, L. 
acidophillus HS101, 
and Bifidobacterium 
bifidum 
Candida spp. - RCT, 55 denture wearers harboring 
Candida spp. with no clinical symptoms 
of oral candidiasis; 
- Probiotic therapy: 1x per day, for 5 
weeks (probiotic or placebo); 
- Palatal swab sample for Candida cells 
quantification and identification. 
- Significant reduction of Candida 
infection after probiotic 
administration; 
- C. albicans was the most prevalent 
species before and after the probiotic 
therapy.  
Reduction of Candida 
infection was 
independent of initial 
Candida level, 
colonizing species or 
age of denture. 
Kraft-Bodi et al. 
2015 [16] 
Oral cavity L. reuteri DSM 
17938 and L. reuteri 
ATCC PTA 5289 
Candida spp.  - RCT, 215 elderly people (60 – 102 
years); 
- Probiotic therapy: 2x per day, for 12 
weeks (placebo or probiotic); 
- Prevalence and amount of Candida 
growth (saliva and plaque samples), oral 
hygiene and gingival inflammation were 
assessed. 
- Significant reduction of Candida 
cells in saliva and plaque after 
probiotic administration; 
- No differences in the levels of 
supragingival plaque or bleeding on 
probing were observed. 
“Strong taste” of the 
tablets and gastric upset 
were compliances 
reported in both control 
and experimental 
groups.  
Pirotta et al. 2004 
[39] 
Urogenital 
tract 
L. rhamnosus and B. 
longum (oral 
powder);  
L. rhamnosus, L. 
delbrueckii, L. 
acidophilus, and 
Streptococcus 
thermophiles 
(vaginal pessary) 
Candida spp.  - RCT, 235 non-pregnant women (18-50 
years) with a short course of oral 
antibiotics administration; 
- Probiotic therapy: powder administration 
2x per day and pessary 1x per day, for 
six days of antibiotic course and four 
days after; 
- Vaginal swab was collected for Candida 
identification; 
- Identification of symptomatic VVC. 
- The use of oral or vaginal forms of 
probiotic bacteria could not prevent 
post-antibiotic vulvovaginitis.  
10 days of probiotic 
therapy may be 
insufficient time for the 
occurrence of 
beneficial effects 
against Candida spp. in 
the vagina.  
Martinez et al. 
2009 [38] 
Urogenital 
tract 
L. rhamnosus GR-1 
and L. reuteri RC-14 
Candida spp.  - RCT, 55 women diagnosed with VVC; 
- Probiotic therapy:  single dose of 
fluconazole plus probiotic or placebo 
once a day, for 4 weeks; 
- Vaginal swab was collected for Candida 
- Probiotic significant reduced vaginal 
discharge, itching and/or burning 
vaginal feeling, dyspareunia and/or 
dysuria; 
- Probiotic reduced the presence of 
Candida spp. 
Mild adverse effects 
were reported, but 
could not be definitely 
associated with 
probiotics 
administration. 
identification; 
- Clinical evaluation to detect signs and 
symptoms of VVC. 
Vicariotto et al. 
2012 [2] 
Urogenital 
tract 
L. fermentum LF10 
and L. acidophilus 
LA02 
(arabinogalactan and 
fructo-
oligosaccharides as 
prebiotics) 
Candida spp. - Thirty female patients (23-64 years); 
- Probiotic therapy: 1x per day for 7 days, 
then 1x every 3 days for further 3 weeks. 
In the following month, 1x per week; 
- Vaginal swabs were collected for yeast 
identification. 
- Probiotic significantly solved 
Candida yeast symptoms in 86.6% 
of patients after 28 days; 
- At the end of the second month, 
recurrences were recorded in 11.5% 
of patients. 
Probiotic may establish 
and maintain a 
protective barrier effect 
against vaginal 
Candida. 
Hu et al. 2013 [1] Urogenital 
tract and Oral 
cavity 
Bifidobacterium and 
Lactobacillus 
(DanActiveTM or 
YoPlusTM yogurt) 
Candida spp.  - 24 women (17 HIV-infected, 7 HIV- 
uninfected); 
- Probiotic therapy: 15-days consuming 
each yogurt. 30-day washout period 
between the two yogurt consumption 
periods; 
- Oral and vaginal culture swabs were 
collected.  
- Less fungal colonization among 
women was observed after probiotic 
consumption; 
- HIV-infected women had 
significantly lower vaginal fungal 
colonization after DanActiveTM 
yogurt consumption. 
Reduced oral fungal 
colonization was 
observed in HIV-
infected women 
consuming probiotic 
yogurts, but not 
statistically significant.  
Kovachev et al. 
2015 [37] 
Urogenital 
tract 
L. acidophilus, L. 
rhamnosus, L. 
delbrueckii subsp. 
bulgaricus, and S. 
thermophiles 
C. albicans - 436 women (17-50 years) with C. 
albicans vaginal infections; 
- Probiotic therapy: antifungals alone 
(fluconazole and fenticonazole) or 
associated with vaginal probiotic agent; 
- Clinical and microbiological tests were 
- Probiotic reduced clinical 
complaints; 
- Probiotic therapy improved the 
investigated parameters: vaginal 
fluorine, vaginal tissue changes and 
pH.  
Local application of 
probiotics may improve 
the efficacy of 
conventional 
antifungals and prevent 
relapse.  
performed.  
Manzoni et al. 
2006 [19] 
Gastrointestin
al tract 
L. casei subspecies 
rhamnosus 
Candida spp.  - RCT, 80 preterm neonates with a very 
low birth weight; 
- Probiotic therapy: human milk alone or 
added with probiotic, for up to 6 weeks;  
- Samples from oropharyngeal, stool, 
gastric aspirate, and rectal specimens) 
were collected to assess fungal 
colonization in the GIT. 
- Human milk supplemented with 
probiotic reduced significantly the 
incidence of Candida enteric 
colonization; 
- Probiotic reduced significantly the 
numbers of fungal isolates.  
Probiotic reduced 
incidence and intensity 
of enteric colonization 
by Candida spp.; 
No adverse events were 
observed.  
Romeo et al. 
2011 [21] 
Gastrointestin
al tract 
L. reuteri (ATCC 
55730) and L. 
rhamnosus (ATCC 
53103) 
Candida spp.  - 249 preterms neonates with a birth 
weight <2500 g and a gestational age 
<37 weeks; 
- Probiotic therapy: breast milk or formula 
milk alone, or supplemented with one 
probiotic, for up to 6 weeks; 
- Clinical evaluations were performed. 
Stool samples, oropharyngeal, and 
gastric aspirate specimens were collected 
for Candida detection. Blood cultures 
and Platelia Candida test were 
conducted for the diagnosis of invasive 
candidiasis. 
- Probiotic reduced significantly 
Candida stool colonization; 
- L. reuteri group had a significant 
higher reduction in gastrointestinal 
symptoms than the L. rhamnosus and 
control groups; 
- Probiotics reduced the incidence of 
abnormal neurological outcome.  
Probiotics may prevent 
gastrointestinal 
colonization by 
Candida, protect from 
late-onset sepsis and 
reduce abnormal 
neurological outcomes 
in preterms. 
Demirel et al. 
2013 [4] 
Gastrointestinal 
tract. 
Saccharomyces 
boulardii 
Candida spp.  - 181 preterm neonates with a gestational 
age ≤32 weeks and birth weight ≤1,500 
g; 
- Probiotic therapy: nystatin suspension 
every 8 h, or breast milk or formula 
supplemented with probiotic once a day; 
- Samples of blood, urine and 
cerebrospinal fluid were collected to 
identify invasive fungal infection. Skin, 
stool or rectal cultures were obtained for 
Candida detection.  
- Candida colonization of the skin and 
stool were similar between probiotic 
and nystatin groups;  
- Clinical sepsis, and number of sepsis 
attacks were significantly lower in 
the probiotics group. 
Prophylactic S. 
boulardii and nystatin 
were equally effective 
in reducing candidal 
colonization and 
invasive fungal 
infection. 
Kumar et al. 2013 
[18] 
Gastrointestin
al tract 
L. acidophillus, L. 
rhamnosum, B. 
longum, B. bifidum, 
S. boulardi, and 
Saccharomyces 
thermophilus 
Candida spp.  - RCT, 150 children (3 months-12 years) 
on broad spectrum antibiotics for at least 
48 h; 
- Probiotic therapy: probiotic or placebo 
2x per day for 7 days; 
- Rectal swab, samples of urine and blood 
were collected for Candida detection. 
- Probiotic therapy avoided a 
significant increase in the number of 
patients colonized by Candida spp.  
- Probiotic significantly reduced the 
presence of Candida in the urine, but 
not in the blood;  
Probiotics may be an 
alternative strategy to 
reduce Candida 
infection in GIT and 
urine in children 
receiving broad-
spectrum antibiotics.  
Roy et al. 2014 
[20] 
Gastrointestin
al tract 
L. acidophilus, 
Bifidobacterium 
lactis, B. longum, 
and B. bifidum  
Candida spp. - RCT, 112 preterm neonates (gestational 
age <37 weeks and birth weight <2,500 
g); 
- Probiotic therapy: breast milk 
supplemented with probiotic or placebo, 
2x per day for up to 6 weeks; 
- Probiotic therapy reduced the 
duration of hospitalization and stool 
fungal colonization; 
- Fungal infection was significant less 
in the probiotic group; 
- Full feed establishment was earlier in 
Probiotics may reduce 
enteral fungal 
colonization and reduce 
invasive fungal sepsis 
in low birth weight 
neonates. 
  
- Clinical evaluations were performed. 
Stool samples and gastric aspirate 
specimens were collected for Candida 
detection.  Blood cultures and Platelia 
Candida test were conducted for the 
diagnosis of invasive candidiasis. 
probiotics group. 
RCT (Randomized Clinical Trial); VVC (Vulvovaginal candidiasis); GIT (Gastrointestinal tract) 
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Summary: 
Probiotics have potential to be worthy allies in the battle against candidiasis. Their 
antifungal effect may be due to the suppression of candidal filamentation and biofilm 
formation. Data indicate that probiotics are useful prophylactic and adjunctive 
therapies against mucosal candidiasis. 
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ABSTRACT  
 Candida is an opportunistic pathogen that causes mucosal and deep systemic 
candidiasis. The emergence of drug resistance, and the side effects of currently 
available antifungals have restricted their use as long-term prophylactic agents for 
candidal infections. Given this scenario, probiotics have been suggested as a useful 
alternative for the management of candidiasis. We analyzed the available data on the 
efficacy of probiotics in candidal colonization of host surfaces. A number of well-
controlled studies indicate that probiotics, particularly lactobacilli, suppress Candida 
growth and biofilm development in vitro. A few clinical trials have also shown the 
beneficial effects of probiotics in reducing oral, vaginal and enteric colonization by 
Candida, alleviation of clinical signs and symptoms and in some cases, reducing the 
incidence of invasive fungal infection in critically ill patients. Probiotics may serve in 
future as a worthy ally in the battle against chronic mucosal candidal infections that 
are all too prevalent. 
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INTRODUCTION 
The high prevalence of the human immunodeficiency virus (HIV) infection 
and other immune compromised populations globally has resulted in resurgence of 
Candida infections. These infections may be present on mucosal surfaces, including 
the oral cavity, oropharynx, esophagus, and vagina, as well as systemically [1]. 
Healthy individual may also be the target of Candida infections as this fungus 
is a commensal organism in human mucosal surfaces, inhabiting one half of the 
human populace as an opportunist pathogen of the gastrointestinal and urogenital 
tracts [2].  However, Wwhen adverse conditions supervene particularly in debilitated 
individuals, Candidathe fungus is capable of causing superficial as well as deep 
invasive candidiasis, including fungaemias. These diseases are essentially caused by 
candidal biofilms attached to body surfaces as opposed to the planktonic form of the 
yeast which exist is the suspended phase. Candida albicans is the most common 
Candida species inhabiting the mucosal surfaces both in health and disease, while 
other species such as C. tropicalis, C. guilliermondii, C. krusei, C. tropicalis, and C. 
glabrata are less frequently isolated.  
A host range of adverse factors predisposes an individual to local or systemic 
candidal infection. The critical factors that precipitate systemic infections These 
includeinclude the very low birth weight neonates [3] and  immunosuppression  as in 
HIV disease, or due to radiation and cytotoxic therapy [4].; Pperturbation of mucosal 
ecosystem or marked changes in the microbial flora ecosystems due to antibiotics or 
corticosteroids; hypoendocrine states such as hypothyroidism, Addison’s disease and 
diabetes mellitus; blood disorders such as acute leukaemia; xerostomia due to 
irradiation or Sjogren’s syndrome, and ill-fitting appliances are predisposing factors 
Formatted: Font: Italic
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for localized candidal infections either in health or diseased states [4]. Thus, Candida 
is considered as an opportunistic pathogen, causing ‘diseases of the diseased’.  
The aim of this review was to explore critically the available in vitro and in 
vivo data on the efficacy of probiotic therapy in managing mucosal candidiasis. For 
this purpose a critical review of the literature was conducted to select pertinent 
articles published in the English literature from 2000 to 2015. An electronic search 
was performed in MEDLINE using the following terms: ‘probiotic or Lactobacillus’ 
AND ‘Candida or candidiasis’ to garner clinical evidence, and ‘probiotic or 
Lactobacillus’ AND ‘Candida’ for the in-vitro studies. Only clinical trials assessing 
Candida infection in the oral cavity, urogenital and gastrointestinal tract were 
included.  
In the following sections we provide an overview of Candida infections, a 
summary of probiotics, in vitro and in vivo evidence of the antifungal effects of 
probiotics, and their possible mechanisms of action, and finally, the safety and risks 
of probiotic therapy. 
 
CANDIDA INFECTIONS 
Oral Candidiasis 
Oral candidiasis can manifest in a variety of clinical guises. The classic triad 
of oral candidiasis is the pseudomembranous, the erythematous (atrophic) and 
hyperplastic variant [4]. 
In addition, there are a number of other Candida-associated lesions where the 
aetiology is multifactorial. These diseases include Candida-associated denture 
stomatitis, angular cheilitis or angular stomatitis, median rhomboid glossitis and the 
Formatted: Don't add space between paragraphs of
the same style
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newly described linear gingival erythema, the microbial aetiology of which is still ill 
understood [4].  
 
Extra-oral and systemic Candida infections 
 Vulvovaginal candida infection (VVC) is the second most common cause of 
vaginitis after bacterial vaginosis and affects millions of women all over the world. 
Transmission of this yeast from the vagina to the mouths of newborns during birth is a 
major portal of oral infections in newborns, leading to the development of thrush [2]. 
 Candida inhabits the gastrointestinal tract (GIT) in almost all humans and most 
of the infections involving Candida are endogenously acquired from the GIT. 
Candida can translocate into the blood stream through the intact gastrointestinal 
mucosa and spread to visceral organs, leading to systemic candidiasis, especially in 
critically ill patients [3]. Disruption of normal physiological barriers, such as gastric 
acidity and perturbations of the indigenous microflora of the colon, facilitate Candida 
overgrowth. 
 Within the GIT, the most common site of infection is the esophagus, but the 
stomach and intestine are also frequently involved. Candida may be associated with 
gastric ulcers, as an opportunistic pathogen that delays ulcer healing and aggravates 
the disease [5]. 
 
Management of candidiasis  
 For some decades, systemic antifungal agents have been successfully used to 
prevent mucosal as well as invasive fungal infections. However, due to the drug side 
effects (nausea, vomiting and diarrhea), and potential emergence of resistant strains, 
antifungal prophylaxis has not been totally successful.  
 6 
 The commonly used antifungals are the polyenes (Nystatin and amphotericin B) 
and , the azoles (fluconazole, itraconazole, voriconazole), flucytosine and the newer 
echinocandins (caspofungin). Interestingly, the biofilm phase of Candida is much 
more resistant to all these antifungals compared with their planktonic counterparts [6]. 
The limited spectrum and toxicity of available antifungals, and the gradual emergence 
of resistance to these drugs are a concern, thus alternative therapies are urgently 
warranted. 
 Alternatives therapies explored thus far against candidal infections include 
natural products such as peptides, oils, polyphenols from teas, and plant extracts [6]. 
Although the results of these products appear to be promising, their toxicity, 
pharmacodynamics and bio tolerance have not been firmly established. 
 
PROBIOTICS 
The use of probiotic bacteria against microbial infections has emerged as an 
alternative therapeutic technique for Candida infections in view of the limitations of 
the currently available antimicrobials.  
Probiotics are defined as live microorganisms that when administered or 
consumed in adequate quantities confer health benefits on the host. Bacteria 
belonging to the genera Lactobacillus and Bifidobacterium and, to a lesser extent, 
Enterococci, Streptococcus and Saccharomyces have often been used as probiotics in 
food supplements for a considerable period of time [7].  
A safe probiotic needs to be of human origin, devoid of intrinsic and 
transmissible antibiotic resistance genes. The functional requirements of a probiotics 
include acid and bile tolerances, adequate adherence and colonization on epithelial 
surfaces, immunestimulation, and antagonistic activity against pathogens [7].  
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Therapeutic potential of probiotics  
In therapeutic terms probiotics are known to reduce Candida infections in 
different organ systems of the human body, and generally considered to be beneficial 
for overall health. For instance probiotics can combat diarrhea, mainly in children, 
relieve lactose intolerance and symptoms of inflammatory bowel diseases [7]. 
Additionally, probiotic bacteria have been investigated for their potential for 
preventing cancers such as colorectal cancer [8], regulating blood pressure [9] and 
suppressing cholesterol levels [10]. The combination of probiotics with traditional 
treatment options are thought to generate better outcomes and disease resolution in 
different loci with only a marginal increase in the treatment cost [7, 11, 12]. 
 
Probiotics as an antimicrobial 
Organisms of the genus Lactobacillus have been traditionally used as 
probiotics for decades and they are deemed worthy as an alternative biological 
approach to combat bacterial and fungal pathogens in the oral cavity, GIT and 
urogenital system [1, 3, 11, 13-21]. It is noteworthy that the antimicrobial effect of 
probiotic bacteria is strain-specific, and hence the selection of probiotics for 
therapeutic purposes should be targeted for specific pathogens and their beneficial 
effects cannot be generalized [14].  
Additionally there are reports of putative anti-viral effect of probiotics mainly 
against respiratory viral pathogens in people of all ages [22]. However, until more 
data are available caution should be exercised in interpreting the available information 
on the antiviral effect of probiotics. 
 
 8 
IN VITRO EVIDENCE OF THE ANTIFUNGAL EFFECTS OF PROBIOTICS 
A number of in vitro studies have demonstrated the antifungal effect of 
polymicrobial combinations of probiotics against human C. albicans isolates from the 
oral cavity, GIT, and genitourinary tract [13, 14, 23-31]. Table 1 illustrates the variety 
and the extent of bacterial strains used to evaluate the candidicidal activity of 
probiotic bacteria, beginning this millennium. Several laboratory methods for the 
detection of the antimicrobial activity of probiotics have been used in the foregoing 
studies. 
The probiotic bacteria that have been investigated against Candida species 
(mainly C. albicans) to date, include Streptococcus salivarius K12 [23], Lactobacillus 
rhamnosus GR-1, L. reuteri RC-14 [25], and also clinical isolates of Lactobacillus [27, 
30].  
Antimicrobial activity of lactobacilli is generally well known. Other Sstudies 
using antagonism in agar diffusion assays  have demonstrated that Lactobacillus 
species inhibit the growth of both Gram-positive and Gram-negative pathogens (e.g. S. 
mutans and Escherichia coli, respectively) [13, 14], in addition to Candida spp. [13, 
14, 25, 27, 30, 32]. C. albicans was found to be more susceptible to the antifungal 
effect of Lactobacillus than C. tropicalis [27]. Moreover, probiotic bacteria and their 
supernatant also exhibited growth inhibitory activities against C. glabrata [32].The 
foregoing studies investigated the most inhibitory bacterial strains against Candida, 
using in vitro tests for antagonism in agar diffusion assays, and attempted to clarify 
the mechanisms of their antifungal action. The production of hydrogen peroxide by 
the probiotics that antagonizes candidal growth was a notable phenomenon observed 
in a number of these studies [27, 30].  
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Hyphae formation and adhesion assays were used to evaluate the effect of 
Other Saccharomyces boulardii [26] and Streptococcus salivarius [23] on C. 
albicans.yeasts, such as Saccharomyces boulardii, in turn, have been tested as 
probiotic against C. albicans. S. boulardiiThe former is a close relative of baker’s 
yeast and appears to secrete an active compound that inhibits filamentation of C. 
albicans and its mycelial development, a crucial virulence attribute of this fungal 
pathogen [26]. S. salivarius K12 was not directly fungicidal, but appeared to inhibit 
Candida adhesion to the substratum and increase the planktonic cells in culture 
medium [23].  
The effect of probiotics may be time dependent. Using a time-kill assay, 
sSome investigators have attempted to reinforce the probiotic effect of bacteria by 
supplementing the medium with chemical adjuvants, such as selenium. The latter is 
an essential micro-mineral that regulates metabolism, and is known to reinforce 
immunity. Selenium nanoparticle-enriched L. plantarum and L. johnsonii cells and 
supernatant have shown higher antifungal activity against C. albicans than controls 
devoid of the nanoparticles . This effect was seen both in planktonic suspensions of 
selenium dioxide-laced lactobacilli, and also in culture supernatants of selenium 
nanoparticle-enriched lactobacilli [24]. These data, yet to be confirmed, exemplify 
how probiotics could be synergized and deserve further studies. 
Experiments on the effect of probiotics on Candida biofilms, as opposed to 
their suspended planktonic phase, provide another fascinating glimpse of how 
probiotics behave [28, 29, 31]. It has been shown that a number of bacteria can 
interfere with the biofilm growth by reducing hyphal development [28, 31], a result 
akin to that described above [26]. Ujaoney et al. [29] cultured C. albicans biofilms on 
denture acrylic strips and challenged them with four commercially available 
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probiotics, individually, in the forms of bacterial suspension or cell-free supernatant. 
They reported that the probiotic cell-free supernatant had a strong and significant 
inhibitory effect on biofilm development  on denture acrylic strips than the bacteria 
per se, indicating that the inhibitory agent is secretedan exometabolites secreted into 
the medium.  
Chew et al. [32], using confocal laser scanning microscopy, also demonstrated 
tThe candidicidal effect of planktonic lactobacilli and their supernatant was also 
demonstrated by Chew et al. [32] against C. glabrata, another common fungal 
pathogen. using confocal laser scanning microscopy [32]  
A summarized in Table 1, tThere is now a convincing body of in vitro data to 
indicate the antifungal effect of probiotics against Candida spp. (Table 1). The 
challenge now is to clarify the mechanisms involved in this activity and harness these 
in further translational work. Further Iinvestigations of the molecular mechanisms 
underlying the probiotic effect using gene expression and related technology are 
likely to yield interesting data in this regard.  
 
IN VIVO EVIDENCE OF THE ANTIFUNGAL EFFECTS OF PROBIOTICS  
 As opposed to the in vitro studies reported above (Table 1), a number of in 
vivo studies have also been performed over the past decade or so to substantiate the 
antifungal activity of probiotics in animals and humans (Table 2). The oral cavity, 
gastrointestinal and urogenital tract have been the major loci of investigation in these 
studies as these sites are susceptible to Candida infections. 
 
Oral cavity 
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 Despite the high prevalence of oral candidal infections in compromised 
predisposed populations groups the world over, and the recalcitrancet and chronicity 
of these diseases, there are only a few in vivo studies evaluating the effect of 
probiotics on suppressing oral candidiasis. These studies indicate that probiotics may 
be a useful adjunct in the battle against oral candidiasis both especially as a 
prophylactic agent and a therapeutic measurein immunocompetent individuals. 
The elderly are a particular group susceptible to oral candidiasis even in health, 
due to the prosthesis (dentures) they frequently wear, as well as and hyposalivation. , 
and possibly Their their weakened immune status may favor the recurrence of 
candidiasis. Two research groups have shown that the daily consumption of probiotic 
(lactobacilli) - laced cheese [15] or lozenges [17] significantly reduce the high yeast 
counts in saliva and biofilms in the elderly. Since biofilms on oral prosthetic devices 
act as potent reservoirs of the yeast, the mechanical removal of biofilms associated 
with the regular use of probiotics that reduce the oral burden of Candida could play a 
major role in preventing oral candidiasis in denture wearers. Interestingly, one study 
reported increased salivary flow as a salutary accompaniment to probiotic 
administration [15]. 
As mentioned fFull denture wearwearersing elderly suffer frequently from 
Candida-associated denture stomatitis [4], which lowers the quality of life in such 
cohorts. Ishikawa et al. [16] have reported that a probiotic product, when regularly 
placed on the palatal surface of maxillary dentures, reduced oral candidal burden in 
healthy denture wearers. These preliminary data imply that multispecies probiotics, 
together with good denture hygiene may help suppress recurrence of these chronic 
infections. Indeed, probiotic therapy together with antifungals may be indicated as a 
safe and effective approach to Candida-associated stomatitis, in order to prevent its 
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Commercial food products with probiotics are now common worldwide since 
available probiotic-laced drink containing Lactobacillus casei and Bifidobacterium 
breve was able to reduce the prevalence of oral Candida in healthy individuals [33]. A 
significant increase in anti-Candida IgA levels was associated with probiotic 
consumption in the latter study[33]. In contrast, the identical product did not 
oral candidal colonization in complete denture wearers [34] and in healthy dentate 
people [35], after four weeks of administration. The lower dose of probiotic intake 
and the small number of individuals included in the latter studies may explain these 
divergent observations.  
 
Urogenital tract 
 Chronic vulvovaginal candidiasis (VVC) is a widely prevalent disease and 
impacts the life quality of thousands of women the world over. Although standard 
antifungals , particularly of the azole group, are effective, there is no alternative 
approach for suppressing these recalcitrant infections. Several groups have therefore 
evaluated the efficacy of probiotics in the treatment and prophylaxis of VVC [1, 2, 12, 
36].  
 Two studies conducted on healthy women have reported that the co-
administration of probiotics with standard antifungal therapy (fluconazole) was more 
effective in reducing symptoms of VVC, including vaginal discharge, pruritus vulvae, 
vulva and vagina erythema, dyspareunia and dysuria, than in a group treated with 
antifungals alone [12, 36]. Clinical improvement was also observed after local 
administration of a commercial slow release probiotic product alone, without an 
antifungal agent, in healthy women with recurrent VVC [2]. In another Similarly, in a 
study conducted in immunocompromised HIV-infected women, who are highly 
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susceptible to recurrent and complicated VVC infection, probiotic yoghurt 
consumption led to a decreased frequency of infection [1]. 
On the contrary, another well controlled study reported that probiotic bacteria 
taken both orally and locally was unable to prevent post-antibiotic VVC in 
immunocompetent individuals who took oral antibiotics [37]. Qualitative and 
quantitative differences in the probiotics strains, as well as the period of probiotics 
administration are likely to be the reasons for the divergent results between the 
foregoing studies. 
 
Gastrointestinal tract 
 Candida species are common inhabitants of the gastrointestinal tract (GIT) of 
humans. Perturbation of the local microbiome however leads to dysbiosis within the 
this ecosystem of the GIT, leading to candidal overgrowth and possible invasive 
infections, especially in infants [21]. 
 Hence, critically illimmunocompromised children, especially preterm 
neonates with low birth weight, have been the target population of a number studiesof 
number studies evaluating the efficacy of probiotics against candidal colonization of 
GIT [3, 19-21]. Within this population,  
 mMost researchers have reported a significant reduction in the incidence and 
intensity of enteric candidal colonization with probiotic-laced human milk, in 
comparison to controls without probiotics, administered either with or without 
concurrent antifungals [19-21]. Important secondary effects of the probiotics observed 
in these studies include reduction of sepsis episodes [3], early establishment of full 
feeding associated with reduction in the duration of hospitalization [20], and the 
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decrease in the incidence of abnormal neurological outcomes associated with late-
onset sepsis [21].  
Broad-spectrum antibiotics are notorious for their ability to cause GIT 
dysbiosis and candidiasis [18, 37]. In immunocompetent children who had received 
broad-spectrum antibiotics presented with such dysbiotic symptoms and candidiasis 
of GIT, probiotic therapy led to a reduction of gastrointestinal candidal colonization 
as well as candiduria – a surrogate marker of invasive fungal infection [18]. 
 
POSSIBLE MECHANISMS OF ACTION OF PROBIOTICS  
Clearly the major attribute of probiotics appears to be the restoration of a 
natural healthy microbiome in a given habitat, turning from a catastrophic, disease-
inducing, dysbiotic microbiota to a healthy, symbiotic, stable equilibrium. A number 
of hypothesis, most unproven as yet, have been proposed for the genesis of this well-
balanced state from disease to health. Probiotics may compete for nutrients and 
receptors on the cell surfaces with the pathogenic microorganisms, thus preventing 
their adhesion and colonization on the mucosal surfaces [2, 29]. Co- and auto-
aggregation of probiotics with the formation of a critical mass required for a healthy 
biofilm development may act as a protective lining against pathogenic infection [30]. 
Apart from the above, the production of biosurfactants that interfere with microbial 
adhesion and desorption [38], the release of exometabolites, such as lactic, acetic and 
capric acid, ,and the production of bacteriocins and hydrogen peroxide (H2O2) are 
other possible attributes postulated as mechanisms for probiotic activity [24-26]. 
Despite such in vitro data on several evidences of the in vitro production ofthe these 
direct effect of probiotics on mucosal candidiasis is yet be shown in a laboratory 
environment mimicking the oral cavity, vagina or the GIT. 
Formatted: Font: (Default) Times New Roman, 12 pt
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 The host response to probiotics is likely to play an important role in probiotic 
mediated microbiome effects. The modulation of both innate and adaptive immune 
systems is probably associated with alteration of cytokines profile and Candida 
recognition by epithelial and immune defense cells [28, 39, 40]. Evidence to imply 
probiotic interference with these host defense factors during candidal infestation is 
still needed. 
With respect to candidal infection, in vitro studies have demonstrated that 
probiotics can were found to reduce filamentation and biofilm development in C. 
albicans, two key virulence attributes of this fungus [25, 28]. As the yeast or the 
blastospore form of Candida, as opposed to the filamentous or hyphal form, is more 
susceptible to phagocytosis [40], probiotics appear to assist the host combat the 
pathogen more effectively by suppressing filamentation. Despite the evidence that 
probiotic bacteria may affect the expression of genes associated with biofilm 
formation and filamentation of Candida species [25], the mechanisms by which 
probiotics affect these yeasts attributes are still unclear, as yet.  
Probiotics administered in tandem with antifungal drugs synergizes clearance 
of Candida [11, 12, 36]. Apart from the obvious antifungal effect of the drug, the role 
of the probiotic under these conditions remains to be elucidated. The increased 
expression of stress-related genes and decreased expression of genes involved in drug 
resistance in Candida, promoted by the probiotics, would possibly increase the fungus 
susceptibility to the antifungal agent administered [25].  
 
SAFETY AND RISKS OF PROBIOTIC THERAPY 
A range of bacteria can has been utilizedsed as probiotics in humans, 
depending on the pathological condition. None of the clinical studies mentioned 
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above have reported adverse effects directly related to probiotics, suggesting their 
safety. HoweverNevertheless, the safety, efficacy and functionality of new probiotics 
bacteria should be tested in healthy as well as in immunocompromised individuals 
prior to their administration as therapeutic agents. 
 
FUTURE PERSPECTIVES AND CONCLUSIONS 
In summary, clinical studies indicate that probiotics may reduce Candida 
colonization on human mucosal surfaces, relieve signs and symptoms of fungal 
infection, and enhance the antifungal effect of conventional therapy, implying that 
probiotics have the potential to sustain a healthy mucosal microbiota, acting both as 
prophylactic and adjunctive therapy against candidiasis. In vitro studies indicate that 
the antifungal effect of probiotics is likely to be due to their interference with 
Candida biofilm development and hyphal differentiation. However, it is premature to 
designate probiotics as an alternative to antifungals, as yet, due to the paucity of 
available clinical trials. In particular, case control clinical trials with adequate patient 
numbers are warranted not only to ascertain the activity of the probiotic formulations, 
but also to evaluate their dosage, administration schedules, side effects, and bio-
dynamics in humans. As with any formulations of live organisms, other concerns that 
need further investigation include the potential for selection of resistant strains, 
mutability, and tolerability on prolonged use, as well as pathogenic potential in 
immunocompromised patients. Given these caveats probiotics may serve in future as 
worthy allies in the battle against chronic mucosal fungal infections. 
Despite a number of in vitroHowever, t and in vivo studies that indicate 
favorable outcomes of probiotics against Candida infections, it is still premature to 
designate probiotics as an alternative to antifungals in yeast infections. Nevertheless 
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the available data imply that probiotics have the potential to be considered a useful 
 
ACKNOWLEDGMENTS 
All authors: no conflicts.  
 18 
REFERENCES 
1. Hu H, Merenstein DJ, Wang C, et al. Impact of eating probiotic yogurt on 
colonization by Candida species of the oral and vaginal mucosa in HIV-
infected and HIV-uninfected women. Mycopathologia 2013; 176(3-4): 
175-81. 
2. Vicariotto F, Del Piano M, Mogna L, Mogna G. Effectiveness of the 
association of 2 probiotic strains formulated in a slow release vaginal 
product, in women affected by vulvovaginal candidiasis: a pilot study. J 
Clin Gastroenterol 2012; 46 Suppl: S73-80. 
3. Demirel G, Celik IH, Erdeve O, Saygan S, Dilmen U, Canpolat FE. 
Prophylactic Saccharomyces boulardii versus nystatin for the prevention 
of fungal colonization and invasive fungal infection in premature infants. 
Eur J Pediatr 2013; 172(10): 1321-6. 
4. Samaranayake LP. Superficial oral fungal infections. Curr Opin Dent 1991; 
1(4): 415-22. 
5. Brzozowski T, Zwolinska-Wcislo M, Konturek PC, et al. Influence of gastric 
colonization with Candida albicans on ulcer healing in rats: effect of 
ranitidine, aspirin and probiotic therapy. Scand J Gastroenterol 2005; 
40(3): 286-96. 
6. Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. 
Candida species: current epidemiology, pathogenicity, biofilm formation, 
natural antifungal products and new therapeutic options. J Med Microbiol 
2013; 62(Pt 1): 10-24. 
 19 
7. Saarela M, Mogensen G, Fonden R, Matto J, Mattila-Sandholm T. Probiotic 
bacteria: safety, functional and technological properties. J Biotechnol 
2000; 84(3): 197-215. 
8. Shida K, Nomoto K. Probiotics as efficient immunopotentiators: 
translational role in cancer prevention. Indian J Med Res 2013; 138(5): 
808-14. 
9. Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood 
pressure: a systematic review and meta-analysis of randomized, 
controlled trials. Hypertension 2014; 64(4): 897-903. 
10. Jones ML, Tomaro-Duchesneau C, Martoni CJ, Prakash S. Cholesterol 
lowering with bile salt hydrolase-active probiotic bacteria, mechanism of 
action, clinical evidence, and future direction for heart health applications. 
Expert Opin Biol Ther 2013; 13(5): 631-42. 
11. Li D, Li Q, Liu C, et al. Efficacy and safety of probiotics in the treatment of 
Candida-associated stomatitis. Mycoses 2014; 57(3): 141-6. 
12. Martinez RC, Franceschini SA, Patta MC, et al. Improved treatment of 
vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus 
rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett Appl Microbiol 
2009; 48(3): 269-74. 
13. Coman MM, Verdenelli MC, Cecchini C, et al. In vitro evaluation of 
antimicrobial activity of Lactobacillus rhamnosus IMC 501®, Lactobacillus 
paracasei IMC 502® and SYNBIO® against pathogens. J Appl Microbiol 
2014; 117(2): 518-27. 
 20 
14. Hasslof P, Hedberg M, Twetman S, Stecksen-Blicks C. Growth inhibition of 
oral mutans streptococci and candida by commercial probiotic 
lactobacilli--an in vitro study. BMC Oral Health 2010; 10: 18. 
15. Hatakka K, Ahola AJ, Yli-Knuuttila H, et al. Probiotics reduce the 
prevalence of oral Candida in the elderly--a randomized controlled trial. J 
Dent Res 2007; 86(2): 125-30. 
16. Ishikawa KH, Mayer MP, Miyazima TY, et al. A multispecies probiotic 
reduces oral Candida colonization in denture wearers. J Prosthodont 
2014; 24(3): 194-9. 
17. Kraft-Bodi E, Jorgensen MR, Keller MK, Kragelund C, Twetman S. Effect of 
probiotic bacteria on oral Candida in frail elderly. J Dent Res 2015; 94(9): 
181S-6S. 
18. Kumar S, Bansal A, Chakrabarti A, Singhi S. Evaluation of efficacy of 
probiotics in prevention of candida colonization in a PICU-a randomized 
controlled trial. Crit Care Med 2013; 41(2): 565-72. 
19. Manzoni P, Mostert M, Leonessa ML, et al. Oral supplementation with 
Lactobacillus casei subspecies rhamnosus prevents enteric colonization by 
Candida species in preterm neonates: a randomized study. Clin Infect Dis 
2006; 42(12): 1735-42. 
20. Roy A, Chaudhuri J, Sarkar D, Ghosh P, Chakraborty S. Role of enteric 
supplementation of probiotics on late-onset sepsis by Candida species in 
preterm low birth weight neonates: a randomized, double blind, placebo-
controlled trial. N Am J Med Sci 2014; 6(1): 50-7. 
21. Romeo MG, Romeo DM, Trovato L, et al. Role of probiotics in the 
prevention of the enteric colonization by Candida in preterm newborns: 
 21 
incidence of late-onset sepsis and neurological outcome. J Perinatol 2011; 
31(1): 63-9. 
22. Lehtoranta L, Pitkaranta A, Korpela R. Probiotics in respiratory virus 
infections. Eur J Clin Microbiol Infect Dis 2014; 33(8): 1289-302. 
23. Ishijima SA, Hayama K, Burton JP, et al. Effect of Streptococcus salivarius 
K12 on the in vitro growth of Candida albicans and its protective effect in 
an oral candidiasis model. Appl Environ Microbiol 2012; 78(7): 2190-9. 
24. Kheradmand E, Rafii F, Yazdi MH, Sepahi AA, Shahverdi AR, Oveisi MR. 
The antimicrobial effects of selenium nanoparticle-enriched probiotics 
and their fermented broth against Candida albicans. Daru 2014; 22: 48. 
25. Kohler GA, Assefa S, Reid G. Probiotic interference of Lactobacillus 
rhamnosus GR-1 and Lactobacillus reuteri RC-14 with the opportunistic 
fungal pathogen Candida albicans. Infect Dis Obstet Gynecol 2012; 2012: 
636474. 
26. Murzyn A, Krasowska A, Stefanowicz P, Dziadkowiec D, Lukaszewicz M. 
Capric acid secreted by S. boulardii inhibits C. albicans filamentous growth, 
adhesion and biofilm formation. PLoS One 2010; 5(8): e12050. 
27. Strus M, Kucharska A, Kukla G, Brzychczy-Wloch M, Maresz K, Heczko PB. 
The in vitro activity of vaginal Lactobacillus with probiotic properties 
against Candida. Infect Dis Obstet Gynecol 2005; 13(2): 69-75. 
28. Thein ZM, Samaranayake YH, Samaranayake LP. Effect of oral bacteria on 
growth and survival of Candida albicans biofilms. Arch Oral Biol 2006; 
51(8): 672-80. 
 22 
29. Ujaoney S, Chandra J, Faddoul F, et al. In vitro effect of over-the-counter 
probiotics on the ability of Candida albicans to form biofilm on denture 
strips. J Dent Hyg 2014; 88(3): 183-9. 
30. Verdenelli MC, Coman MM, Cecchini C, Silvi S, Orpianesi C, Cresci A. 
Evaluation of antipathogenic activity and adherence properties of human 
Lactobacillus strains for vaginal formulations. J Appl Microbiol 2014; 
116(5): 1297-307. 
31. Vilela SF, Barbosa JO, Rossoni RD, et al. Lactobacillus acidophilus ATCC 
4356 inhibits biofilm formation by C. albicans and attenuates the 
experimental candidiasis in Galleria mellonella. Virulence 2015; 6(1): 29-
39. 
32. Chew SY, Cheah YK, Seow HF, Sandai D, Than LT. Probiotic Lactobacillus 
rhamnosus GR-1 and Lactobacillus reuteri RC-14 exhibit strong antifungal 
effects against vulvovaginal candidiasis-causing Candida glabrata isolates. 
J Appl Microbiol 2015; 118: 1180-90  
33. Mendonça FH, Santos SS, Faria Ida S, Goncalves e Silva CR, Jorge AO, Leao 
MV. Effects of probiotic bacteria on Candida presence and IgA anti-
Candida in the oral cavity of elderly. Braz Dent J 2012; 23(5): 534-8. 
34. Sutula J, Coulthwaite L, Thomas L, Verran J. The effect of a commercial 
probiotic drink on oral microbiota in healthy complete denture wearers. 
Microb Ecol Health Dis 2012; 23. 
35. Sutula J, Coulthwaite LA, Thomas LV, Verran J. The effect of a commercial 
probiotic drink containing Lactobacillus casei strain Shirota on oral health 
in healthy dentate people. Microb Ecol Health Dis 2013; 24. 
 23 
36. Kovachev SM, Vatcheva-Dobrevska RS. Local probiotic therapy for vaginal 
Candida albicans infections. Probiotics Antimicrob Proteins 2015; 7(1): 
38-44. 
37. Pirotta M, Gunn J, Chondros P, et al. Effect of lactobacillus in preventing 
post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. 
BMJ 2004; 329(7465): 548. 
38. Zakaria Gomaa E. Antimicrobial and anti-adhesive properties of 
biosurfactant produced by lactobacilli isolates, biofilm formation and 
aggregation ability. J Gen Appl Microbiol 2013; 59(6): 425-36. 
39. Wagner RD, Johnson SJ. Probiotic lactobacillus and estrogen effects on 
vaginal epithelial gene expression responses to Candida albicans. J 
Biomed Sci 2012; 19: 58. 
40. Gantner BN, Simmons RM, Underhill DM. Dectin-1 mediates macrophage 
recognition of Candida albicans yeast but not filaments. EMBO J 2005; 
24(6): 1277-86. 
 
ICJME Conflict of Interest Forms Matsubara
Click here to access/download
ICJME Conflict of Interest Forms
coi_disclosure_Matsubara.pdf
ICJME Conflict of Interest Forms Bandara
Click here to access/download
ICJME Conflict of Interest Forms
coi_disclosure_Bandara.pdf
ICJME Conflict of Interest Forms Mayer
Click here to access/download
ICJME Conflict of Interest Forms
coi_disclosure_Mayer.pdf
ICJME Conflict of Interest Forms Samaranayake
Click here to access/download
ICJME Conflict of Interest Forms
coi_disclosure_Samaranayake.pdf
